Home
report store
epidermal growth factor receptor non small cell lung cancer epidemiology forecast

Epidermal Growth Factor Receptor Non-small Cell Lung Cancer (EGFR-NSCLC)– Epidemiology Forecast – 2036

Published Date : 2026

Pages : 164

Region : United States, Japan, EU4 & UK

Summary
TOC Table of Content
LOT
- Sample Request

epidermal growth factor receptor non small cell lung cancer epidemiology forecast

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Insights and Trends

According to DelveInsight’s analysis, the total prevalent cases of EGFR NSCLC were ~117,800 in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
EGFR-mutated NSCLC is more prevalent in Asian counties such as Japan, with mutation rates estimated at 45%, compared to 15% in Western countries. Majorly due to genetic predisposition, lower smoking rates among Asian patients, and distinct environmental factors that contribute to a higher likelihood of oncogenic driver mutations.
Males face a higher lifetime risk of developing lung cancer and experience greater mortality compared to females. This disparity is partly attributed to lifestyle factors, as men are more likely to engage in cigarette smoking, alcohol consumption, high-calorie diets, and drug use, all of which elevate lung cancer risk.
Population aging, urbanization, environmental pollution, and improved diagnostic capabilities are expected to sustain the global NSCLC burden over the next decade, despite ongoing tobacco control efforts. Prevention, early detection, and precision medicine adoption will remain key determinants of future trends.

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Epidemiology Forecast

2025 Incident Cases of EGFR NSCLC: ~117,800
2036 Projected Incident Cases of EGFR NSCLC: ~128,300
EGFR NSCLC Growth Rate (2026–2036): 0.8% CAGR

DelveInsight's ‘Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the EGFR NSCLC, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Study Period	2022–2036
Historical Year	2022–2025
Forecast Period	2026–2036
Base Year	2026
Geographies Covered	North America : The US; Europe: Germany, France, Italy, and Spain and the UK; Asia-Pacific: Japan
EGFR NSCLC Epidemiology CAGR (Study period/Forecast period)	0.8% (2026-2036)
EGFR NSCLC Epidemiology Segmentation Analysis	Patient Burden Assesment Total Incident Cases of NSCLC Gender-specific Incident Cases of NSCLC Age-specific Incident Cases of NSCLC Total Incident Cases of NSCLC by Histology Total Incident Cases of NSCLC by Stage Total Incident Cases of EGFR NSCLC Line-wise Treated Cases of EGFR NSCLC

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Understanding and Diagnosis Algorithm

EGFR NSCLC Overview

EGFR is a protein in cells that helps them grow. A mutation in the gene for EGFR can make it grow too much, which can cause cancer. There are different types of EGFR mutations, including deletions or insertions and point mutations. In test results, individuals may be identified as having an EGFR 19 deletion or an EGFR L858R point mutation, which are the most common types of EGFR mutations. These mutations are typically treated the same way. Amongst the EGFR mutations that are tested for in lung cancer, a few rare types are treated differently than the more common EGFR mutations. The major example of this in lung cancer is EGFR exon 20 insertions.

EGFR NSCLC Diagnosis

In general, there are two ways to detect EGFR mutations. The best way is through comprehensive next-generation sequencing (NGS). This type of testing places tissue from a patient’s tumor (gathered from a biopsy) in a machine that looks for a large number of possible biomarkers at one time. There may be some situations where a patient cannot undergo the biopsy needed to perform NGS, so liquid biopsy is recommended. A liquid biopsy can look for certain biomarkers in a patient’s blood.

Further details are provided in the report.

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Epidemiology

Key Findings from EGFR NSCLC Epidemiological Analysis and Forecast

According to DelveInsight’s estimates, the total number of incident cases of NSCLC in the 7MM was nearly 540,000 cases in 2025 and is projected to increase during the forecasted period.
The total number of incident cases of NSCLC in the United States was nearly 202,900 in 2025.
In 2025, adenocarcinoma (~116,000 cases) accounted for the largest share of incident NSCLC cases in the United States, followed by squamous cell carcinoma, while large cell carcinoma comprised the smallest proportion.
The total number of cases of EGFR NSCLC in the United States was estimated to be nearly 30,400 in 2025.
NSCLC shows a slight male predominance and is most common in individuals aged =65 years. However, cases among people younger than 65 are increasing, likely due to changing smoking patterns, environmental and occupational exposures, air pollution, and improved early diagnostic detection.

Scope of the Report

The report covers a segment of an executive summary, a descriptive overview of EGFR NSCLC, explaining its causes, signs and symptoms, and pathogenesis.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

EGFR NSCLC patient population forecast

Report Key Strengths

Epidemiology-based (epi-based) bottom-up forecasting
11-year forecast
Patient burden trends (by geography)

FAQs

What are the disease risks, burdens, and unmet needs of EGFR NSCLC? What will be the growth opportunities across the 7MM concerning the patient population with EGFR NSCLC?
What is the historical and forecasted EGFR NSCLC patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

1. Key Insights

2. Report Introduction

3. Executive Summary of EGFR-NSCLC

5. Epidemiology Forecast Methodology

4. EGFR-NSCLC Epidemiology Overview at a Glance

4.1. Patient Share (%) Distribution by Country in 2025 in the 7MM

4.2. Patient Share (%) Distribution by Country in 2036 in the 7MM

5. Disease Background and Overview

5.1. Introduction

5.2. Structure and Mechanism of EGFR

5.3. Types of EGFR Mutation in NSCLC

5.4. Risk Factors Associated With EGFR-mutated NSCLC

5.5. Diagnosis

5.5.1. Biomarker Testing for EGFR Mutation

5.5.2. Diagnosis Algorithm of EGFR

5.5.3. Diagnosis Guidelines

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Assumptions and Rationale

6.3. Total Incident Cases of EGFR-NSCLC in the 7MM

6.4. The United States

6.4.1. Total Incident Cases of NSCLC in the United States

6.4.2. Gender-specific Incident Cases of NSCLC in the United States

6.4.3. Age-specific Incident Cases of NSCLC in the United States

6.4.4. Total Incident Cases of NSCLC by Histology in the United States

6.4.5. Total Incident Cases of NSCLC by Stage in the United States

6.4.6. Total Incident Cases of EGFR-NSCLC in the United States

6.4.7. Line-wise Treated Cases of EGFR-NSCLC in the United States

6.5. EU4 and the UK

6.5.1. Total Incident Cases of NSCLC in EU4 and the UK

6.5.2. Gender-specific Incident Cases of NSCLC in EU4 and the UK

6.5.3. Age-specific Incident Cases of NSCLC in EU4 and the UK

6.5.4. Total Incident Cases of NSCLC by Histology in EU4 and the UK

6.5.5. Total Incident Cases of NSCLC by Stage in EU4 and the UK

6.5.6. Total Incident Cases of EGFR-NSCLC in EU4 and the UK

6.5.7. Line-wise Treated Cases of EGFR-NSCLC in EU4 and the UK

6.6. Japan

6.6.1. Total Incident Cases of NSCLC in Japan

6.6.2. Gender-specific Incident Cases of NSCLC in Japan

6.6.3. Age-specific Incident Cases of NSCLC in Japan

6.6.4. Total Incident Cases of NSCLC by Histology in Japan

6.6.5. Total Incident Cases of NSCLC by Stage in Japan

6.6.6. Total Incident Cases of EGFR-NSCLC in Japan

6.6.7. Line-wise Treated Cases of EGFR-NSCLC in Japan

7. Appendix

7.1. Bibliography

7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Tables:

List of Table

Table 1: Summary of EGFR-NSCLC Epidemiology (2025–2036)

Table 2: Types of EGFR Mutation

Table 3: Molecular and Biomarker-directed Therapy for Advanced or Metastatic Diseasea,b

Table 4: First-line Treatment for EGFR Gene Mutation-positive: Exon 19 Deletion or L858R Mutation-positive

Table 5: EGFR Biomarker Epidemiology

Table 6: Total Incident Cases of EGFR-NSCLC in the 7MM (2022–2036)

Table 7: Total Incident Cases of NSCLC in the United States (2022–2036)

Table 8: Gender-specific Incident Cases of NSCLC in the United States (2022–2036)

Table 9: Age-specific Incident Cases of NSCLC in the United States (2022–2036)

Table 10: Total Incident Cases of NSCLC by Histology in the United States (2022–2036)

Table 11: Total Incident Cases of NSCLC by Stage (at diagnosis) in the United States (2022–2036)

Table 12: Total Incident Cases of Advanced/Metastatic NSCLC in the United States (2022–2036)

Table 13: Total Incident Cases of EGFR-NSCLC in the United States (2022–2036)

Table 14: Line-wise Treated Cases of NSCLC in the United States (2022–2036)

Table 15: Total Incident Cases of NSCLC in EU4 and the UK (2022–2036)

Table 16: Gender-specific Incident Cases of NSCLC in Germany (2022–2036)

Table 17: Gender-specific Incident Cases of NSCLC in France (2022–2036)

Table 18: Gender-specific Incident Cases of NSCLC in Italy (2022–2036)

Table 19: Gender-specific Incident Cases of NSCLC in Spain (2022–2036)

Table 20: Gender-specific Incident Cases of NSCLC in the UK (2022–2036)

Table 21: Gender-specific Incident Cases of NSCLC in EU4 and the UK (2022–2036)

Table 22: Age-specific Incident Cases of NSCLC in Germany (2022–2036)

Table 23: Age-specific Incident Cases of NSCLC in France (2022–2036)

Table 24: Age-specific Incident Cases of NSCLC in Italy (2022–2036)

Table 25: Age-specific Incident Cases of NSCLC in Spain (2022–2036)

Table 26: Age-specific Incident Cases of NSCLC in the UK (2022–2036)

Table 27: Age-specific Incident Cases of NSCLC in EU4 and the UK (2022–2036)

Table 28: Total Incident Cases of NSCLC by Histology in Germany (2022–2036)

Table 29: Total Incident Cases of NSCLC by Histology in France (2022–2036)

Table 30: Total Incident Cases of NSCLC by Histology in Italy (2022–2036)

Table 31: Total Incident Cases of NSCLC by Histology in Spain (2022–2036)

Table 32: Total Incident Cases of NSCLC by Histology in the UK (2022–2036)

Table 33: Total Incident Cases of NSCLC by Histology in EU4 and the UK (2022–2036)

Table 34: Total Incident Cases of NSCLC by Stage (at diagnosis) in Germany (2022–2036)

Table 35: Total Incident Cases of NSCLC by Stage (at diagnosis) in France (2022–2036)

Table 36: Total Incident Cases of NSCLC by Stage (at diagnosis) in Italy (2022–2036)

Table 37: Total Incident Cases of NSCLC by Stage (at diagnosis) in Spain (2022–2036)

Table 38: Total Incident Cases of NSCLC by Stage (at diagnosis) in the UK (2022–2036)

Table 39: Total Incident Cases of NSCLC by Stage (at diagnosis) in EU4 and the UK (2022–2036)

Table 40: Total Incident Cases of Advanced/Metastatic NSCLC in the EU4 and the UK (2022–2036)

Table 41: Total Incident Cases of EGFR-NSCLC in Germany (2022–2036)

Table 42: Total Incident Cases of EGFR-NSCLC in France (2022–2036)

Table 43: Total Incident Cases of EGFR-NSCLC in Italy (2022–2036)

Table 44: Total Incident Cases of EGFR-NSCLC in Spain (2022–2036)

Table 45: Total Incident Cases of EGFR-NSCLC in the UK (2022–2036)

Table 46: Total Incident Cases of EGFR-NSCLC in EU4 and the UK(2022–2036)

Table 47: Line-wise Treated Cases of NSCLC in Germany (2022–2036)

Table 48: Line-wise Treated Cases of NSCLC in France (2022–2036)

Table 49: Line-wise Treated Cases of NSCLC in Italy (2022–2036)

Table 50: Line-wise Treated Cases of NSCLC in Spain (2022–2036)

Table 51: Line-wise Treated Cases of NSCLC in the UK (2022–2036)

Table 52: Line-wise Treated Cases of NSCLC in EU4 and the UK (2022–2036)

Table 53: Total Incident Cases of NSCLC in Japan (2022–2036)

Table 54: Gender-specific Incident Cases of NSCLC in Japan (2022–2036)

Table 55: Age-specific Incident Cases of NSCLC in Japan (2022–2036)

Table 56: Total Incident Cases of NSCLC by Histology in Japan (2022–2036)

Table 57: Total Incident Cases of NSCLC by Stage (at diagnosis) in Japan (2022–2036)

Table 58: Total Incident Cases of Advanced/Metastatic NSCLC in the Japan (2022–2036)

Table 59: Total Incident Cases of EGFR-NSCLC in Japan (2022–2036)

Table 60: Line-wise Treated Cases of NSCLC in Japan (2022–2036)

List of Figures:

List of Figures

Figure 1: Mechanism of Action of EGFR

Figure 2: Types of EGFR Mutation in NSCLC

Figure 3: Risk Factors Associated With EGFR-mutated NSCLC

Figure 4: Tumor Biomarker Testing Rate

Figure 5: Total Incident Cases of EGFR-NSCLC in the 7MM (2022–2036)

Figure 6: Total Incident Cases of NSCLC in the United States (2022–2036)

Figure 7: Gender-specific Incident Cases of NSCLC in the United States (2022–2036)

Figure 8: Age-specific Incident Cases of NSCLC in the United States (2022–2036)

Figure 9: Total Incident Cases of NSCLC by Histology in the United States (2022–2036)

Figure 10: Total Incident Cases of NSCLC by Stage (at diagnosis) in the United States (2022–2036)

Figure 11: Total Incident Cases of EGFR-NSCLC in the United States (2022–2036)

Figure 12: Line-wise Treated Cases of NSCLC in the United States (2022–2036)

Figure 13: Total Incident Cases of NSCLC in EU4 and the UK (2022–2036)

Figure 14: Gender-specific Incident Cases of NSCLC in EU4 and the UK (2022–2036)

Figure 15: Age-specific Incident Cases of NSCLC in EU4 and the UK (2022–2036)

Figure 16: Total Incident Cases of NSCLC by Histology in EU4 and the UK (2022–2036)

Figure 17: Total Incident Cases of NSCLC by Stage (at diagnosis) in EU4 and the UK (2022–2036)

Figure 18: Total Incident Cases of EGFR-NSCLC in EU4 and the UK (2022–2036)

Figure 19: Line-wise Treated Cases of NSCLC in EU4 and the UK (2022–2036)

Figure 20: Total Incident Cases of NSCLC in Japan (2022–2036)

Figure 21: Gender-specific Incident Cases of NSCLC in Japan (2022–2036)

Figure 22: Age-specific Incident Cases of NSCLC in Japan (2022–2036)

Figure 23: Total Incident Cases of NSCLC by Histology in Japan (2022–2036)

Figure 24: Total Incident Cases of NSCLC by Stage (at diagnosis) in Japan (2022–2036)

Figure 25: Total Incident Cases of EGFR-NSCLC in Japan (2022–2036)

Figure 26: Line-wise Treated Cases of NSCLC in Japan (2022–2036)

Tags:

License Type

Offer